rs10882398 — PLCE1

Intronic PLCE1 variant where the A allele raises systolic blood pressure and confers genome-wide significant risk for preeclampsia and pregnancy-induced hypertension through impaired podocyte calcium signaling and vascular pressure regulation

See your personal result for PLCE1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PLCE1 and Vascular Pressure Regulation — When a Calcium Signaling Enzyme Shapes Blood Pressure and Pregnancy Risk

Tucked within the introns of PLCE1 on chromosome 10, rs10882398 marks a variant that influences blood pressure across the lifespan and reaches its most dramatic clinical expression during pregnancy. PLCE1 (phospholipase C epsilon 1) encodes an enzyme that hydrolyzes membrane phospholipids to generate second messengers — primarily IP3 (inositol trisphosphate) and diacylglycerol11 IP3 (inositol trisphosphate) and diacylglycerol
IP3 triggers calcium release from intracellular stores; DAG activates protein kinase C — together they regulate vascular smooth muscle tone, podocyte survival, and endothelial function. The A allele at this locus nudges systolic blood pressure upward, amplifies risk for preeclampsia, and — through the kidney's filtration cells — leaves carriers less able to tolerate the haemodynamic demands of hypertension.

The Mechanism

PLCE1 is expressed in two cell types that directly regulate vascular pressure and renal filtration: glomerular podocytes22 glomerular podocytes
the specialized foot-process cells that form the kidney's filtration barrier; podocyte loss is a hallmark of hypertensive kidney disease and arteriolar smooth muscle cells in the kidney glomerulus. In endothelial cells it operates downstream of Rap-1 signaling to elevate intracellular calcium via the IP3 pathway, driving prostacyclin (PGI2) synthesis — an endogenous vasodilatory and antithrombotic mediator.

When PLCE1 function is compromised, two pathways toward elevated pressure are implicated. First, impaired endothelial PLCε-to-calcium signaling reduces PGI2 output, tipping the prostanoid balance toward vasoconstriction. Second, the kidney's pressure-buffering capacity diminishes: in mice, PLCE1 deficiency produces no renal phenotype at normal blood pressure but causes 20-fold increased albuminuria, glomerulosclerosis, and podocyte loss when hypertension is induced33 20-fold increased albuminuria, glomerulosclerosis, and podocyte loss when hypertension is induced, consistent with a genotype that tolerates normal pressures but amplifies injury under stress. During pregnancy, the haemodynamic demands of placentation — which normally require spiral artery remodelling and careful blood pressure management — may expose this vulnerability acutely.

rs10882398 is an intronic variant and does not change the PLCE1 protein sequence. It is a tag SNP marking a regulatory haplotype that modifies PLCE1 expression levels or splicing in relevant tissues. The exact molecular mechanism by which this haplotype reduces PLCE1 function has not been characterized at the biochemical level.

The Evidence

The blood pressure association is genome-wide significant and replicated across hundreds of thousands of participants. The GWAS Catalog records an A-allele association with systolic blood pressure at p=9×10⁻²³ (beta=0.019 mmHg per A allele), and with preeclampsia/pregnancy-induced hypertension combined at OR=1.11 (95% CI 1.08–1.14; p=2×10⁻¹³).

Tyrmi et al., JAMA Cardiology 202344 Tyrmi et al., JAMA Cardiology 2023 conducted the largest preeclampsia GWAS to date, combining 16,743 women with preeclampsia from the Finnish FINNPEC and FinnGen cohorts, the Estonian Biobank, and the international InterPregGen consortium. Among 19 genome-wide significant associations — 13 of them novel — PLCE1 was identified as one of seven loci carrying genes previously known to regulate blood pressure (alongside NPPA, NPR3, TNS2, FURIN, RGL3, and PREX1), reinforcing the concept that preeclampsia shares genetic architecture with essential hypertension.

Changalidis et al., Genes 202255 Changalidis et al., Genes 2022 confirmed the rs10882398 signal independently: a meta-analysis of FinnGen and UK Biobank GWAS summary statistics across 24 pregnancy complications identified rs10882398 in PLCE1 as one of three loci reaching genome-wide significance (p=8.9×10⁻⁹) for pregnancy hypertension.

The mechanistic evidence for PLCE1 in blood pressure comes from Atchison et al., American Journal of Physiology Renal Physiology 202066 Atchison et al., American Journal of Physiology Renal Physiology 2020: PLCE1-null mice develop severe glomerulosclerosis under experimentally induced hypertension, with albuminuria 20-fold above wild-type controls, establishing a clear gene-dose relationship between PLCE1 status and pressure-mediated kidney injury.

Practical Actions

For A-allele carriers, the clinically actionable implications run in two directions: blood pressure control is more protective than average because the PLCE1-deficient kidney is disproportionately sensitive to elevated pressure; and pregnancy represents a period of amplified cardiovascular risk requiring proactive monitoring.

Dietary sodium restriction achieves measurably larger blood pressure reductions in individuals with genetically elevated pressure set-points at GWAS-identified loci. At the A allele's beta of ~0.02 mmHg per copy, homozygous carriers accumulate a meaningful additive genetic pressure contribution that compounds with modifiable risk factors like sodium, obesity, and sleep-disordered breathing.

Monitoring with 24-hour ambulatory blood pressure measurement (ABPM) rather than clinic readings captures early nocturnal hypertension — the pattern most predictive of end-organ damage in genetically elevated pressure phenotypes. For women planning pregnancy, early-trimester blood pressure baseline and low-dose aspirin prophylaxis (75–150 mg daily from 12 weeks) represent evidence-based preeclampsia risk reduction strategies endorsed by ACOG and NICE for elevated-risk individuals.

Interactions

PLCE1 rs10882398 shares pathway biology with rs932764 (PLCE1 hypertension susceptibility variant associated with antihypertensive drug response differences between racial groups; PMID:31327267) — both are PLCE1 intronic variants, and their LD relationship and combined effect on PLCE1 expression have not been fully characterized.

The blood pressure associations at rs10882398 overlap with the FGF5 and RGL3 blood-pressure loci co-identified in the same preeclampsia GWAS, suggesting that the genetic architecture of pregnancy hypertension mirrors essential hypertension — multiple additive loci, each contributing a small but real pressure increment, with the cumulative burden materializing clinically during the haemodynamic stress of pregnancy.

Genotype Interpretations

What each possible genotype means for this variant.

TT Normal

Your PLCE1 genotype is not associated with elevated blood pressure or pregnancy hypertension risk

You carry two copies of the T allele at rs10882398, which is the GRCh38 reference allele and the most common genotype globally (approximately 38% of people by Hardy-Weinberg estimate across all ancestries, and about 28% in Europeans where the A allele is particularly common). This genotype is not associated with elevated systolic blood pressure or increased preeclampsia risk in GWAS meta-analyses. Your PLCE1 calcium-signaling capacity at this locus is genetically intact.

AT Intermediate

One copy of the PLCE1 blood-pressure risk allele — modestly elevated systolic blood pressure and preeclampsia risk

PLCE1 encodes a calcium-mobilizing enzyme expressed in kidney podocytes and glomerular arterioles. Animal and human data show that reduced PLCE1 function impairs the kidney's ability to buffer haemodynamic stress, making blood pressure elevation more injurious per mmHg. One A allele reduces PLCE1 expression/function proportionally less than two copies — the additive model means heterozygotes sit between the TT and AA risk categories.

For women, the preeclampsia association is the most clinically actionable implication. Preeclampsia affects 2–8% of pregnancies globally; PLCE1 A-allele carriers face a ~11% higher odds per copy, bringing the OR for heterozygotes to approximately 1.11. This is comparable in magnitude to many established preeclampsia risk factors (prior preeclampsia, nulliparity, obesity) and qualifies for aspirin prophylaxis consideration when combined with other risk indicators.

AA High Risk

Two copies of the PLCE1 blood-pressure risk allele — elevated systolic blood pressure risk and significantly increased preeclampsia susceptibility

PLCE1 is critical for the kidney's ability to withstand haemodynamic stress. In PLCE1-deficient mice, hypertension triggers 20-fold greater protein leakage through the glomerular filter than in wild-type animals, with progressive glomerulosclerosis and podocyte loss. The A allele at rs10882398 is an intronic tag SNP that reduces PLCE1 expression or function; two copies create the greatest genetically-determined reduction at this locus, leaving the kidney's filtration barrier most vulnerable to pressure peaks.

In pregnancy, the haemodynamic stress is acute: blood volume expands by ~45%, cardiac output rises sharply, and the placenta requires successful spiral artery remodelling that depends partly on trophoblast invasion and vasoactive signalling. Reduced PLCE1-mediated endothelial calcium signalling may impair prostacyclin production in placental vessels, contributing to the shallow invasion and vasoconstriction that characterize preeclampsia. The A allele appears in a Mendelian randomisation context consistent with blood pressure being a causal intermediate on the path to preeclampsia at this locus.

Blood pressure monitoring should begin pre-pregnancy in AA carriers to establish a baseline. Any upward trend in the second trimester (the normal dip should occur) warrants earlier intervention than standard protocols trigger in lower-risk women.